Undisclosed Subcutaneous APJ Agonist
/ BioAge Labs, JiKang Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 07, 2025
APJ agonist program advancement
(The Manila Times)
- "The Company continued to advance its oral and parenteral APJ agonist development strategy....Both programs are targeting IND submissions in 2026."
IND • Obesity
1 to 1
Of
1
Go to page
1